TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37231634
Drug: Intelligent physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intelligent physical exercise training (IPET) for 1 hour weekly during paid working hours for 2 years, plus recommendations for 30-minute leisure time physical activity 6 days/week (LPA)
Study: 37231670
Drug: CT-P47 (162
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P47 (162 mg/0.9 mL, single subcutaneous dose)
Study: 37231670
Drug: EU-tocilizumab (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: EU-tocilizumab (single subcutaneous dose)
Study: 37232002
Drug: Asenapine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine (10 or 20 mg/day)
Study: 37232534
Drug: Self-management strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management strategies and medications (prescription and over-the-counter)
Study: 37232940
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose 10 mg/kg of L-AmB
Study: 37232940
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg of L-AmB on D1, and 5 mg/kg of L-AmB on D3
Study: 37232940
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg of L-AmB daily for 2 weeks (control)
Study: 37233785
Drug: PET agent
Normalized name: Pet Pectillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET agent A
Study: 37233785
Drug: PET agent
Normalized name: Pet Pectillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET agent B
Study: 37234006
Drug: Music Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Therapy (MT) in NICU
Study: 37234006
Drug: Music Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Therapy (MT) postdischarge
Study: 37234014
Drug: Free medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free medicine distribution (access to 128 medicines with no out-of-pocket costs for 3 years)
Study: 37234014
Drug: Usual medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual medicine access
Study: 37235505
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no stimulant exposure)
Study: 37235976
Drug: Chemotherapy (Cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Cisplatin plus Pemetrexed)
Study: 37236007
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy with agalsidase beta
Study: 37236033
Drug: Adavosertib 225
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib 225 mg BID orally for 2.5 days and carboplatin AUC 5 mg/ml·min intravenously
Study: 37236221
Drug: dihydroartemisinin-piperaquine plus
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: dihydroartemisinin-piperaquine plus tafenoquine (300 mg)
Study: 37236221
Drug: primaquine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: primaquine (15 mg) plus dihydroartemisinin-piperaquine
Study: 37236398
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg once daily for up to 3 years
Study: 37236636
Drug: M9241 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M9241 at 4, 8, 12, or 16.8 µg/kg every 4 weeks plus avelumab 10 mg/kg every 2 weeks (dose levels 1-4)
Study: 37236636
Drug: M9241 16.8 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: M9241 16.8 µg/kg every 4 weeks plus avelumab 800 mg once a week for 12 weeks followed by every 2 weeks (DL5/dose expansion)
Study: 37236636
Drug: M9241 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: M9241 plus avelumab (all dose levels)
Study: 37236666
Drug: Prophylactic single
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic single dose of fibrinogen, in addition to standard of care
Study: 37236666
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care without study medication prior to skin incision
Study: 37236706
Drug: Pre-radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-radiation therapy (RT) characteristics
Study: 37236899
Drug: Pilocarpine microneedle
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine microneedle patches
Study: 37236995
Drug: PTX-COVID19-B vaccine
Normalized name: Hepatitis B Vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTX-COVID19-B vaccine (16-µg, 40-µg, or 100-µg doses)
Study: 37236995
Drug: PTX-COVID19-B vaccine
Normalized name: Hepatitis B Vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTX-COVID19-B vaccine (all doses)
Study: 37236995
Drug: PTX-COVID19-B vaccine
Normalized name: Hepatitis B Vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTX-COVID19-B vaccine (40-µg dose)
Study: 37237172
Drug: GSK3368715 (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3368715 (50, 100, and 200 mg)
Study: 37237172
Drug: GSK3368715 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3368715 (100 mg)
Study: 37237416
Drug: Metreleptin, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metreleptin, a recombinant analog of human leptin, administered as an adjunct to diet.
Study: 37239618
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein supplementation (20 g of whey protein isolate) with resistance training (RT) for 12 weeks, twice a week.
Study: 37239618
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received an isocaloric drink (20 g of maltodextrin) with resistance training (RT) for 12 weeks, twice a week.
Study: 37242129
Drug: Aversive conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aversive conditioning (lipid infusion via naso-duodenal catheter)
Study: 37242129
Drug: Sham conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham conditioning (sham infusion)
Study: 37242222
Drug: Infants fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants fed formula supplemented with 0.2 g/L 2'-FL + 2.2 g/L GOS
Study: 37242222
Drug: Infants fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants fed formula supplemented with 1.0 g/L 2'-FL + 1.4 g/L GOS
Study: 37242723
Drug: Immediate-release tacrolimus
Normalized name: tacrolimus Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release tacrolimus (TAC-IR)
Study: 37242723
Drug: Extended-release tacrolimus
Normalized name: tacrolimus Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release tacrolimus (TAC-LCP)
Study: 37243171
Drug: Vaccination (SARS-CoV-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination (SARS-CoV-2 vaccine)
Study: 37243336
Drug: Temsirolimus (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (15 mg/m weekly)
Study: 37243345
Drug: Eplerenone 50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 50 mg PO BID (n = 20)
Study: 37244266
Drug: Befotertinib (75-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befotertinib (75-100 mg once daily)
Study: 37244266
Drug: Icotinib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib (125 mg three times per day)
Study: 37244367
Drug: Brief clinician-administered
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief clinician-administered Skills Training in Affective and Interpersonal Regulation (Brief STAIR)
Study: 37244367
Drug: web-administered STAIR
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: web-administered STAIR (webSTAIR)
Study: 37244454
Drug: Intravaginal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal estrogen (1 g conjugated estrogen intravaginal cream, 0.625 mg/g)
Study: 37244626
Drug: Intensity Modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity Modulated Radiation Therapy with Simultaneous Integrated Boost
Study: 37244626
Drug: 3-Dimensional Conformal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-Dimensional Conformal Radiation Therapy with Sequential Boost
Study: 37245018
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (individual and group) in addition to standard treatment for 10 participants (6 weekly sessions)
Study: 37245018
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment only for 5 participants (control group)
Study: 37245191
Drug: Low-dose interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose interleukin-2 (IL2)
Study: 37245522
Drug: CPX-351 (intravenous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPX-351 (intravenous, 100 mg/m²)
Study: 37245517
Drug: Care bundle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care bundle intervention including early intensive lowering of systolic blood pressure (target <140 mm Hg), strict glucose control (target 6·1-7·8 mmol/L for non-diabetics and 7·8-10·0 mmol/L for diabetics), antipyrexia treatment (target body temperature ≤37·5°C), and rapid reversal of warfarin-related anticoagulation (target INR <1·5) within 1 hour of treatment.
Study: 37245855
Drug: Treatment Effectiveness
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Effectiveness Assessment (TEA)
Study: 37245989
Drug: Rivaroxaban (approved
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (approved dose)
Study: 37246588
Drug: Dasatinib discontinuation
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib discontinuation
Study: 37246588
Drug: Off-treatment period
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off-treatment period
Study: 37247166
Drug: SCT510 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCT510 (3 mg/kg infusion)
Study: 37247166
Drug: Bevacizumab (Avastin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (Avastin, 3 mg/kg infusion)
Study: 37247190
Drug: Voxelotor 1500
Normalized name: Voxelotor
DrugBank: Voxelotor (DB14975)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Voxelotor 1500 mg daily
Study: 37247819
Drug: Carotenoid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotenoid group (10 mg L and 2 mg Z softgel)
Study: 37247876
Drug: rhTNK-tPA 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTNK-tPA 0.25 mg/kg (single bolus) to a maximum of 25 mg
Study: 37247876
Drug: standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard medical therapy
Study: 37247957
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg oral prednisone daily for five consecutive days
Study: 37248330
Drug: Modified alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Modified alteplase formulation (0.2 mg/kg body weight)
Study: 37248330
Drug: Current alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current alteplase formulation (0.2 mg/kg body weight)
Study: 37248912
Drug: Pamrevlumab (35-mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamrevlumab (35-mg/kg intravenous infusions every 2 weeks for 2 years)
Study: 37249512
Drug: YTB323 (autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: YTB323 (autologous CD19-directed CAR T-cell therapy)
Study: 37249512
Drug: Tisagenlecleucel (traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tisagenlecleucel (traditional CAR T-cell therapy)
Study: 37249860
Drug: COVID-19 vaccination
Normalized name: COVID-19 VACCINE ADENOVIRUS-26
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 vaccination (2 doses)
Study: 37249860
Drug: COVID-19 vaccination
Normalized name: COVID-19 VACCINE ADENOVIRUS-26
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 vaccination (3 doses)
Study: 37249860
Drug: COVID-19 vaccination
Normalized name: COVID-19 VACCINE ADENOVIRUS-26
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 vaccination (2 and 3 doses)
Study: 37250148
Drug: Entinostat plus
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entinostat plus exemestane (oral exemestane 25 mg/day)
Study: 37250148
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus exemestane (oral exemestane 25 mg/day)
Study: 37251062
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both body-centred and mind-centred practices
Study: 37251511
Drug: PSQI Use
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSQI Use of Sleep Medications
Study: 37251628
Drug: PD1-19bbz infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PD1-19bbz infusion
Study: 37252109
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin 750 mg three times daily for 100 days
Study: 37252983
Drug: Cocoa extract
Normalized name: Cocoa extract
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa extract (500 mg of cocoa flavanols per day)
Study: 37253044
Drug: hCG +
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG + biotin (20 mg/day)
Study: 37253139
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Recent Oral Contraceptive or Hormonal Contraceptive Vaginal Ring Users)
Study: 37253491
Drug: Neoadjuvant chemo-immunotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemo-immunotherapy with camrelizumab and cisplatin (75-80 mg/m2)
Study: 37253803
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of basiliximab with ruxolitinib
Study: 37254058
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (ropivacaine 0.4% + dexamethasone 4 mg, 20 mL per side at the level of surgery) plus postoperative opioid analgesia
Study: 37254243
Drug: Simple low-cost
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple low-cost intervention to empower dietary salt reduction, details on dosage and duration not available.
Study: 37254818
Drug: Medication review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication review intervention (n=196)
Study: 37255194
Drug: YK-1169 (2.5 g,
Approvals — FDA: no, EMA: no, PMDA: no
Description: YK-1169 (2.5 g, 2-h infusion, every 8 hours for 7 days)
Study: 37255194
Drug: Cefepime (2 g)
DrugBank: Cefepime (DB01413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefepime (2 g)
Study: 37255194
Drug: Avibactam (0.5 g)
DrugBank: Avibactam (DB09060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Avibactam (0.5 g)
Study: 37255689
Drug: Active intradermal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active intradermal acupuncture group
Study: 37255689
Drug: Sham intradermal
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham intradermal acupuncture group
Study: 37255729
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatment as usual
Study: 37256099
Drug: High-dose tadalafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tadalafil
Study: 37256186
Drug: Neoadjuvant Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant Toripalimab (240mg, every 3 weeks) plus double platinum-based chemotherapy
Study: 37256193
Drug: 0.8ng/kg endotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8ng/kg endotoxin injection
Study: 37256238
Drug: Supervised high-intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised high-intensity interval training (3 times weekly for 6 months)
Study: 37256536
Drug: TT (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT (treatment group)
Study: 37256614
Drug: Circulating cardiomyocyte
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Circulating cardiomyocyte cfDNA measured after anthracycline therapy
Study: 37256621
Drug: Hydrocortisone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (10 days treatment)
Study: 37256863
Drug: Benznidazole (BNZ)
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole (BNZ) 7.5 mg/kg/d administered in two daily doses for 60 days
Study: 37256863
Drug: Benznidazole (BNZ)
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole (BNZ) 7.5 mg/kg/d
Study: 37256885
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) using 100% oxygen at a pressure of 2.0-2.4 atmospheres absolute (203-243 kPa) for 90 minutes, five times per week
Study: 37256885
Drug: Subgroup analysis
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup analysis based on pre-existing respiratory disease, smoking history, and applied treatment pressure
Study: 39651791
Drug: Blinatumomab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab plus chemotherapy
Study: 37257422
Drug: Standard steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard steroid eye drops
Study: 37257422
Drug: Standard steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard steroid eye drops plus vasoconstrictor eye drops and cold compress
Study: 37257422
Drug: Enhanced steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced steroids plus vasoconstrictor eye drops and cold compress
Study: 37257564
Drug: SQ-LNS (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ-LNS (20 g/d)
Study: 37258715
Drug: MDMA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (100 mg) and LSD (100 µg)
Study: 37259124
Drug: ParkinsonAKTIV intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ParkinsonAKTIV intervention (online platform for guiding non-pharmacological treatment decisions)
Study: 37259248
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of ketone ester (KE)
Study: 37259323
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine treatment
Study: 37259567
Drug: Azacitidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacitidine (75 mg/m2 days 1-7) + Lenalidomide (2.5 or 5 mg days 1-21) + Donor lymphocyte infusions (0.5×10^6-1.5×10^7 cells/kg)
Study: 37259567
Drug: Azacitidine +
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine + Lenalidomide + Donor lymphocyte infusions
Study: 37259592
Drug: Experimental occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental occupational therapy plus intensive standard rehabilitation
Study: 37259693
Drug: Apraclonidine 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apraclonidine 0.5% solution, administered as two drops to the most affected eye.
Study: 37260158
Drug: Pamiparib 60
Normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamiparib 60 mg orally twice daily (BID)
Study: 37260158
Drug: Pamiparib 60
Normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamiparib 60 mg orally BID
Study: 37260160
Drug: Endocare (VR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocare (VR solution)
Study: 37260312
Drug: Medical interval
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical interval (from first consultation to appropriate antibiotics administration)
Study: 37261364
Drug: Atazanavir 2dd300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir 2dd300 mg
Study: 37261531
Drug: Eliapixant 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eliapixant 25 mg
Study: 37261531
Drug: Eliapixant 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eliapixant 75 mg
Study: 37261531
Drug: Eliapixant 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eliapixant 150 mg
Study: 37261654
Drug: Treatment-emergent pain
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent pain interference
Study: 37261654
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor receipt
Study: 37261654
Drug: Treatment-emergent endocrine
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent endocrine symptoms
Study: 37261654
Drug: Treatment-emergent physical
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent physical function decline
Study: 37261664
Drug: Estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valerate 2-6 mg plus spironolactone 100-200 mg
Study: 37261664
Drug: PrEP (tenofovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP (tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg)
Study: 37261804
Drug: Camrelizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab (200 mg IV every 2 weeks), Apatinib (250 mg oral once daily), Temozolomide (200 mg/m2 IV once daily on days 1-5)
Study: 37261831
Drug: Chemotherapy (fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (fluorouracil or capecitabine, with some receiving doublet chemotherapy or bevacizumab)
Study: 37261831
Drug: Treatment-first group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-first group
Study: 37261839
Drug: Low-dose atropine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose atropine 0.02%